September 30, 2024 by The Mount Sinai Hospital Researchers at the Icahn School of Medicine at Mount Sinai have made a promising breakthrough in the treatment of small cell lung cancer (SCLC). Their study, published in Science Advances and titled “ATR Inhibition Activates Cancer Cell cGAS/STING-Interferon Signaling and Promotes Anti-Tumor Immunity in Small Cell Lung...
Tag: <span>Drug combination</span>
Post
Researchers conduct clinical trial of a specific drug combination for lethal brain cancer glioblastoma
by Will Sansom, University of Texas Health Science Center at San Antonio Credit: Pixabay/CC0 Public Domain The Mays Cancer Center at The University of Texas Health Science Center at San Antonio recently conducted a clinical trial combining two drugs in patients with recurrent, high-grade glioblastoma (GBM). The Mays Cancer Center, one of the four National Cancer...
Post
Researchers test drug combination as means to prevent drug resistance in cancer cells
by Leslie Cantu, Medical University of South Carolina Histopathology representative images of stomach hyperkeratosis and thymus cortical degeneration. (A) H&E stained images of stomach sections from a vehicle control mouse (left panel) and a Doxil treated mouse (right panel). Images shown at ×10 magnification. Arrow highlights hyperkeratosis. (B) H&E stained images of thymus sections from...
Post
New drug combination shows promise in treating acute myeloid leukemia
by Peter MacCallum Cancer Centre Treatment with a histone deacetylase inhibitor induces production of interferon by immune cells, which causes differentiation of leukaemia cells into normal blood cells and ultimately their death (differentiated cells are marked with an arrow). Credit: Peter MacCallum Cancer Centre Research led by Peter Mac and published in Cancer Discovery has found a...
Post
Drug combination reduces the risk of asthma attacks
by Rutgers University Credit: CC0 Public Domain A global study of asthma patients by Rutgers and an international team of researchers found a combination of two drugs dramatically reduces the chances of suffering an asthma attack. Results from the clinical trial called MANDALA, published in The New England Journal of Medicine, show that a combination of...
Post
Drug combination that might prove effective for one in three glioblastoma patients
by Steve Yozwiak, Translational Genomics Research Institute Glioblastoma multiform. Credit: Hellerhoff/Wikimedia Commons, CC BY-SA 3.0 Based on the findings of a new study led by the Translational Genomics Research Institute (TGen), part of City of Hope, a coast-to-coast clinical trial is planned that, if successful, could lead to FDA approval of the first new drug treatment in...
Post
An AI model can help predict adverse events from new drug combinations
by American Association for Cancer Research Credit: Unsplash/CC0 Public Domain Preliminary data from an artificial intelligence model could potentially predict side effects resulting from new combination therapies, according to results presented at the AACR Annual Meeting 2022, held April 8-13. “Clinicians are challenged by the real-world problem that new combination therapies could lead to unpredictable...
Post
Drug combination shows effectiveness in patients with recurrent ER-positive endometrial cancer
by Dana-Farber Cancer Institute Credit: Unsplash/CC0 Public Domain A combination therapy that targets cancer cells from within and without caused tumors to shrink or stabilize in 75% of patients with recurrent or persistent estrogen receptor- (ER-) positive endometrial cancer, results from a recent clinical trial show. Trial leaders from Dana-Farber Cancer Institute will present the...
Post
Drug combination shows meaningful responses for malignant peritoneal mesothelioma patient
UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER HOUSTON – A phase II study led by researchers from The University of Texas MD Anderson Cancer Center found that treatment with atezolizumab and bevacizumab was well-tolerated and resulted in a 40% objective response rate in patients with advanced malignant peritoneal mesothelioma, rare cancer in the lining...
Post
Three-drug combination moves forward for advanced breast cancer
by Institute of Cancer Research Breast cancer cells. Credit: Ewa Krawczyk A combination of three drugs is safe and shows signs of effectiveness in treating some patients with previously treated advanced breast cancer, a clinical trial shows. The ‘triplet therapy’ combines the hormone therapy fulvestrant with two targeted drugs, called palbociclib and taselisib, that block cells from multiplying...